Silexion Therapeutics Ltd. (SLXN)
Silexion Therapeutics Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Ramat Gan, IL. The stock last traded at $0.46, down 55.81% on the session, giving a market capitalisation of $191,649. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of -0.25 implies it has historically moved less than the broad market.
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Silexion Therapeutics Ltd. is most often compared with the following Healthcare names: